On the stock market since 2009, it operates in the world of health and science. It has 4,766 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $476.2M in the vault; even if every debt were paid off, $28.7M would remain.
A loss of $103.5M against $788.1M in annual sales. And on top of that, sales fell from the year before.
The sales tempo runs behind the sector. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, EVOTF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EVOTF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.